Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank A Post

Showing results (161-170 of 171) with videos related to

Pageof 18
Sort By:
BMC Infectious Diseases|April 25, 2018
Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin AmericaYanink Caro-Vega, Anna Schultze, Anne Marie W Efsen, et al.
AIDS (London, England)|April 2, 2019
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trialsSamir K Gupta, Frank A Post, José R Arribas, et al.
Nature Communications|January 31, 2026
Safety and biologic activity of a bispecific T cell receptor targeting HIV Gag in males living with HIV: a first-in-human trialLinos Vandekerckhove, Julie Fox, Borja Mora-Peris, et al.
Lancet (London, England)|July 27, 2020
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialKenneth H Mayer, Jean-Michel Molina, Melanie A Thompson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2008
Predictors of renal outcome in HIV-associated nephropathyFrank A Post, Lucy J Campbell, Lisa Hamzah, et al.
AIDS (London, England)|May 31, 2024
MAVMET trial: maraviroc and/or metformin for metabolic dysfunction associated fatty liver disease in adults with suppressed HIVLeanne McCabe, James E Burns, Arash Latifoltojar, et al.
The Journal of Infectious Diseases|October 3, 2017
Evaluating the Impact of Functional Genetic Variation on HIV-1 ControlPaul J McLaren, Sara L Pulit, Deepti Gurdasani, et al.
Plos Medicine|October 19, 2013
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)Amanda Mocroft, Jens D Lundgren, Miriam Lewis Sabin, et al.
The Lancet. HIV|January 7, 2023
Recommendations for defining preventable HIV-related mortality for public health monitoring in the era of Getting to Zero: an expert consensusSara E Croxford, Veronique Martin, Sebastian B Lucas, et al.
International Journal of Cancer|June 20, 2019
Cervical cancer risk in women living with HIV across four continents: A multicohort studyEliane Rohner, Lukas Bütikofer, Kurt Schmidlin, et al.
Pageof 18

Showing results (161-170 of 171) with videos related to

Sort By:
Pageof 18
BMC Infectious Diseases|April 25, 2018
Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin AmericaYanink Caro-Vega, Anna Schultze, Anne Marie W Efsen, et al.
AIDS (London, England)|April 2, 2019
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trialsSamir K Gupta, Frank A Post, José R Arribas, et al.
Nature Communications|January 31, 2026
Safety and biologic activity of a bispecific T cell receptor targeting HIV Gag in males living with HIV: a first-in-human trialLinos Vandekerckhove, Julie Fox, Borja Mora-Peris, et al.
Lancet (London, England)|July 27, 2020
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialKenneth H Mayer, Jean-Michel Molina, Melanie A Thompson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2008
Predictors of renal outcome in HIV-associated nephropathyFrank A Post, Lucy J Campbell, Lisa Hamzah, et al.
AIDS (London, England)|May 31, 2024
MAVMET trial: maraviroc and/or metformin for metabolic dysfunction associated fatty liver disease in adults with suppressed HIVLeanne McCabe, James E Burns, Arash Latifoltojar, et al.
The Journal of Infectious Diseases|October 3, 2017
Evaluating the Impact of Functional Genetic Variation on HIV-1 ControlPaul J McLaren, Sara L Pulit, Deepti Gurdasani, et al.
Plos Medicine|October 19, 2013
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)Amanda Mocroft, Jens D Lundgren, Miriam Lewis Sabin, et al.
The Lancet. HIV|January 7, 2023
Recommendations for defining preventable HIV-related mortality for public health monitoring in the era of Getting to Zero: an expert consensusSara E Croxford, Veronique Martin, Sebastian B Lucas, et al.
International Journal of Cancer|June 20, 2019
Cervical cancer risk in women living with HIV across four continents: A multicohort studyEliane Rohner, Lukas Bütikofer, Kurt Schmidlin, et al.
Pageof 18